<DOC>
	<DOCNO>NCT00003102</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody locate tumor cell either kill deliver tumor-killing substance without harm normal cell . PURPOSE : Phase I/II trial study effectiveness monoclonal antibody therapy treat patient advanced kidney cancer .</brief_summary>
	<brief_title>Monoclonal Antibody Therapy Treating Patients With Advanced Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Define safety iodine I 131 chimeric monoclonal antibody G250 ( 131I MOAB cG250 ) patient advance renal cell carcinoma . II . Determine maximum tolerate dose ( MTD ) 131I MOAB cG250 . III . Describe pharmacokinetics biodistribution 131I MOAB cG250 . IV . Determine response rate 131I MOAB cG250 MTD . OUTLINE : This dose escalation study . Initially patient receive scout dose IV iodine I 131 chimeric monoclonal antibody G250 ( 131I MOAB cG250 ) 10 minute determine whole body clearance . One week later , patient receive incremental dos IV 131I MOAB cG250 10 minute 2-3 day interval 2-6 week . Dose escalation begin least 8 week last infusion 131I MOAB cG250 . In absence dose limit toxicity first 3 patient treat , subsequent cohort 3 patient receive escalate dos 131I MOAB cG250 schedule . If dose limit toxicity occur 4 6 patient treat give dose level , dose escalation cease next low dose declare maximum tolerate dose ( MTD ) . Treatment continue recovery toxic effect occur , begin 8 12 week follow last course 131I MOAB cG250 . Patients achieve complete remission , partial remission , stable disease receive 3 course treatment . Treatment cease disease progression reach follow 8 week 131I MOAB cG250 . PROJECTED ACCRUAL : This study accrue maximum 48 patient , 24 patient per Phase , anticipate enrollment 2 patient per month 24 month .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove renal cell carcinoma Clinical presentation consistent metastatic renal cell carcinoma Bidimensionally measurable disease No CNS tumor involvement PATIENT CHARACTERISTICS : Age : 16 Performance status : Karnofsky 70100 % Life expectancy : At least 6 week Hematopoietic : WBC least 3,500/mm3 Platelet count least 100,000/mm3 Prothrombin time le 1.3 time control Hepatic : Serum bilirubin great 1 mg/dL Renal : Serum creatinine great 2 mg/dL Cardiovascular : No New York Heart Association Class III/IV Other : No serious infection illness Not pregnant lactate Effective contraception require fertile patient No hypercalcemia great 12.5 mg/dL symptomatic PRIOR CONCURRENT THERAPY : Biologic therapy : At least 6 week since prior immunotherapy Chemotherapy : At least 6 week since prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No significant prior radiation therapy entire pelvis and/or lumbosacral spine Surgery : Not specify Other : No concurrent antibiotic</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
</DOC>